In CML, the identification of the BCR-ABL1 fusion gene, resulting from the t(9;22)(q34;q11) translocation known as the Philadelphia chromosome (Ph) [1,2], has been a groundbreaking discovery that led to the development of targeted therapies like tyrosine kinase inhibitors (TKIs), drastically improving patient outcomes [3]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.